Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C

Journal of Medical Virology

Volumn 79, Issue 6, 2007, Pages 701-713

  Desombere, Isabelle ^a   Van Vlierberghe, Hans ^b   Weiland, Ola ^c   Hultgren, Catharina ^c   Sällberg, Matti ^c   Quiroga, Juan ^d   Carreño, Vicente ^d   Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Fundacion para el Estudio de Las Hepatitis Virales   (Spain)

Author keywords

Algorithm; Early stopping rule; HCV; Humoral response; Interferon therapy

Indexed keywords

ALPHA INTERFERON; ANTIBODY; HUMAN MONOCLONAL ANTIBODY; NS3 ANTIBODY; NS4A ANTIBODY; NS5A ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ALGORITHM; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PREDICTION; PREDICTOR VARIABLE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALGORITHMS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARRIER PROTEINS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 34248165175     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20846     Document Type: Article

References (52)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562.
2. Bassett SE, Brasky KM, Lanford RE. 1998. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72:2589-2599.
3. Beld M, Penning M, van Putten M, Lukashov V, van den Hoek A, McMorrow M, Goudsmit J. 1999. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology 29:1288-1298.
4. Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, Boom R. 2002. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 40:788-793.
5. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
6. Bertoletti A, Ferrari C. 2003. Kinetics of the immune response during HBV and HCV infection. Hepatology 38:4-13.
7. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. 1994. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331:1607-1611.
8. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211-218.
9. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in hepatitis C patients. Blood 106: 1175-1182.
10. Carlsson TR, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E, Weiland O. 2005. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 12:473-480.
11. Cerino A, Mondelli MU. 1991. Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies. J Immunol 147:2692-2696.
12. Chang JC, Seidel C, Ofenloch B, Jue DL, Fields HA, Khudyakov YE. 1999. Antigenic heterogeneity of the bepatitis C virus NS4 protein as modeled with synthetic peptides. Virology 257:177-190.
13. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR. 1999. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116:135-143.
14. Ciurea A, Hunziker L, Klenerman P, Hengartner H, Zinkernagel RM. 2001. Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Exp Med 193:297-305.
15. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449.
16. Davis GL. 2002. Monitoringof viral levels during therapy of hepatitis C. Hepatology 36:S145-S151.
17. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652.
18. Desombere, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. 2005. Comparison of qualitative (Cobas Amplicor HCV 2.0 versus VERSANT HCV RNA) and quantitative (Cobas Amplicor HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) assays for HCV RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol 43:2590-2597.
19. Dou XG, Talekar G, Chang J, Dai X, Li L, Bonafonte MT, Holloway B, Fields HA, Khudyakov YE. 2002. Antigenic heterogeneity of the hepatitis C virus NS5A protein. J Clin Microbiol 40:61-67.
20. EASL. 1999. International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 30:956-961.
21. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394-15399.
22. Ferenci P. 2004. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24 (Suppl 2):25-31.
23. Frangeul L, Cresta P, Perrin M, Duverlie G, Khorsi H, Musset L, Opolon P, Huraux JM, Lunel F. 1998. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon. J Hepatol 28:538-543.
24. Gao B, Hong F, Radaeva S. 2004. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39:880-890.
25. Kalams SA, Walker BD. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199-2204.
26. Keeffe EB, Davis GL. 2002. Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX. Rev Gastroenterol Disord. 2:34-40.
27. Khudyakov YuE, Khudyakova NS, Jue DL, Lambert SB, Fang S, Fields HA. 1995. Linear B-cell epitopes of the NS3-NS4-NS5 proteins of the hepatitis C virus as modeled with synthetic peptides. Virology 206:666-672.
28. Knolle PA, Kremp S, Hohler T, Krummenauer F, Schirmacher P, Gerken G. 1998. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 5:399-406.
29. Komatsu F, Takasaki K. 1999. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients. Liver 19:375-380.
30. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. 2000. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 38:4171-4179.
31. Masalova OV, Lakina EI, Abdulmedzhidova AG, Atanadze SN, Semiletov YA, Shkurko TV, Burkov AN, Ulanova TI, Pimenov VK, Novikov W, Khudyakov YE, Fields H, Kushch AA. 2002. Characterization of monoclonal antibodies and epitope mapping of the NS4 protein of hepatitis C virus. Immunol Lett 83:187-196.
32. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
33. Moradpour D, Brass V, Penin F. 2005. Function follows form: the structure of the N-terminal domain of HCV NS5A. Hepatology 42:732-735.
34. Neville JA, Prescott LE, Bhattacherjee V, Adams N, Pike I, Rodgers B, El-Zayadi A, Hamid S, Dusheiko GM, Saeed AA, Haydon GH, Simmonds P. 1997. Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus. J Clin Microbiol 35:3062-3070.
35. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI. 2002. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 9:429-437.
36. Nolte FS, Fried MW, Shiffman ML, Ferreira-Gonzalez A, Garrett CT, Schiff ER, Polyak SJ, Gretch DR. 2001. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 39:4005-4012.
37. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
38. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. 2000. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211-218.
39. Prince AM, Brotman B, Lee DH, Ren L, Moore BS, Scheffel JW. 1999. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J Infect Dis 180:987-991.
40. Sallberg M, Ruden U, Magnius LO, Norrby E, Wahren B. 1991. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 30:59-68.
41. Sallberg M, Zhang ZX, Chen M, Jin L, Birkett A, Peterson DL, Milich DR. 1996. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J Gen Virol 77 Pt 11:2721-2728.
42. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, Follett EA, Yap PL, Marsden H. 1993. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol 31:1493-1503.
43. Strader DB, Wright T, Thomas DL, Seeff LB. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
44. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H, Yanagihara O, Ohta Y. 1996. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 23:1330-1333.
45. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395-1406.
46. Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. 2003. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77:862-870.
47. Tillmann HL, Wiegand J, Glomb I, Jelineck A, Picchio G, Wedemeyer H, Manns MP. 2005. Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. Z Gastroenterol 43:11-16.
48. Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. 2003. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial. J Viral Hepat 10:460-466.
49. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. 2003. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 41:3212-3220.
50. Wright-Minogue J, Yao N, Zhang R, Butkiewicz NJ, Baroudy BM, Lau JY, Hong Z. 2000. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors. J Hepatol 32:497-504.
51. Zhang ZX, Chen M, Sonnerborg A, Sallberg M. 1994. Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. Clin Diagn Lab Immunol 1:290-294.
52. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. 1997. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 25:1245-1249.